Abstract
Poor adherence and persistence can have a major negative impact on the long-term clinical effectiveness of recombinant human growth hormone (r-hGH) treatment. However, real-time monitoring of adherence and persistence can be difficult. The easypod™ injection device is an electronic auto-injector for r-hGH (Saizen®, Merck Serono S.A. – Geneva, Switzerland) that includes an automatic memory feature for monitoring injection dose history. The easypod™ device records the dose of r-hGH injected, as well as the time and date of each injection. The cumulative dose history can be viewed on the screen of the easypod™ device as a calendar or by individual entry per injection. Based on a pre-programmed dosing schedule, missed or incomplete doses are displayed. The easypod™ connection kit allows uploading of the dose history to a secure online database, subsequently enabling the physician or nurse, using a personal computer, to view and print graphical and schematic data displays, use the data for calculations and export to other computing programmes. easypod™ is the first r-hGH injection device to enable accurate monitoring of treatment adherence and persistence, thereby providing an essential tool for optimizing r-hGH treatment outcome.
Keywords: Adherence, administration, electronic auto-injector, growth hormone, injection device, recombinant, persistence, recombinant human growth hormone, easypodTM injection, Turner syndrome
Current Drug Therapy
Title: Electronic Recording of Growth Hormone Dosing History: The Easypod™ Auto-Injector
Volume: 5 Issue: 4
Author(s): Francois-Xavier Lion
Affiliation:
Keywords: Adherence, administration, electronic auto-injector, growth hormone, injection device, recombinant, persistence, recombinant human growth hormone, easypodTM injection, Turner syndrome
Abstract: Poor adherence and persistence can have a major negative impact on the long-term clinical effectiveness of recombinant human growth hormone (r-hGH) treatment. However, real-time monitoring of adherence and persistence can be difficult. The easypod™ injection device is an electronic auto-injector for r-hGH (Saizen®, Merck Serono S.A. – Geneva, Switzerland) that includes an automatic memory feature for monitoring injection dose history. The easypod™ device records the dose of r-hGH injected, as well as the time and date of each injection. The cumulative dose history can be viewed on the screen of the easypod™ device as a calendar or by individual entry per injection. Based on a pre-programmed dosing schedule, missed or incomplete doses are displayed. The easypod™ connection kit allows uploading of the dose history to a secure online database, subsequently enabling the physician or nurse, using a personal computer, to view and print graphical and schematic data displays, use the data for calculations and export to other computing programmes. easypod™ is the first r-hGH injection device to enable accurate monitoring of treatment adherence and persistence, thereby providing an essential tool for optimizing r-hGH treatment outcome.
Export Options
About this article
Cite this article as:
Lion Francois-Xavier, Electronic Recording of Growth Hormone Dosing History: The Easypod™ Auto-Injector, Current Drug Therapy 2010; 5 (4) . https://dx.doi.org/10.2174/157488510792927474
DOI https://dx.doi.org/10.2174/157488510792927474 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of L-Arginine and Selenium on Metabolic Features, Insulin Resistance and Hepatic Function Tests in Obese Women
Current Nutrition & Food Science Serotonin 5-HT2A and 5-HT2C Receptors as Potential Targets for Modulation of Psychostimulant Use and Dependence
Current Topics in Medicinal Chemistry Cognitive Behavioral Therapy in Prodromal Psychosis
Current Pharmaceutical Design Zopiclone as Positive Control in Studies Examining the Residual Effects of Hypnotic Drugs on Driving Ability
Current Drug Safety Multiple Sequence Alignment as a Workbench for Molecular Systems Biology
Current Bioinformatics New Treatments for COPD in the Elderly
Current Pharmaceutical Design Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Engineering Antibodies for Therapy
Current Pharmaceutical Biotechnology Histone Post-translational Modifications to Target Memory-related Diseases
Current Pharmaceutical Design Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Current Medicinal Chemistry Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine Epidemics of Obesity and Metabolic Disorders: Are Dietary Fats or Sugars Involved?
Current Nutrition & Food Science Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery